Please login to the form below

Not currently logged in

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

Bind Accurin nanotechnology

Pfizer is to research nanomedicines for several diseases in a partnership with Bind Therapeutics that could be $210m per product developed.

The deal focuses on Bind's targeted therapeutics called Accurins, which the company says can outperform conventional drugs by selectively seeking out diseased tissues and cells.

This means there is a higher drug concentration at the necessary site of action, meaning a more effective and safe medicine.

No specific therapy areas were mention by the company, although Bind has said Accurins have the potential to improve patient outcomes in oncology, inflammatory diseases and cardiovascular disorders.

Under the terms of the agreement, both companies will work on preclinical research, while Pfizer will then have the exclusive option to pursue development and commercialisation of selected Accurins.

In return, Bind could receive upfront and development milestone payments totalling $50m and regulatory and sales milestone payments of about $160m for each Accurin commercialised. There will also be tiered royalties on potential future sales.

This is the second major deal Bind has made with a large pharma company this year following a $226m+ deal with Amgen in January.

As noted in the PMLiVE article, Future imperfect: How breakthrough technology can support healthcare, nanotechnology is predicted to have a large impact on healthcare in the coming years, with nanomaterials already being used in the production processes of other industries.

This includes products such as plasma screens, car paints and batteries for mobile phones.

“This is our second collaboration focused on developing novel Accurins based on Bind's platform for targeted and programmable therapeutics and further validates the importance of targeted nanomedicines as a strategic technology for the pharmaceutical industry,” said Scott Minick, president and CEO of Bind.

8th April 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....